- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05873634
HeartShare : combinaison des omiques, du phénotypage profond et des dossiers de santé électroniques pour les sous-types d'insuffisance cardiaque et les cibles de traitement
Étude de phénotypage profond HeartShare
HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.
Aperçu de l'étude
Statut
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Laura Alagna
- Numéro de téléphone: 312-695-6765
- E-mail: heartsharestudy@northwestern.edui
Lieux d'étude
-
-
California
-
Sacramento, California, États-Unis, 95817
- Recrutement
- University of California Davis
-
Contact:
- Maiya Her
- Numéro de téléphone: 916-734-0230
-
Chercheur principal:
- Nipavan Chiamvimonvat, MD
-
Sous-enquêteur:
- Javier Lopez, MD
-
Sous-enquêteur:
- Martin Cadeiras, MD
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Northwestern University
-
Contact:
- Laura Alagna
- Numéro de téléphone: 312-695-6765
- E-mail: laura.alagna@northwesterne.du
-
Chercheur principal:
- Sadiya Khan, MD
-
Chercheur principal:
- Laura Rasmussen-Torvik, PhD, MPH
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Pas encore de recrutement
- Mass General Brigham
-
Chercheur principal:
- Greg Lewis, MD
-
Contact:
- Diane Cocca-Spofford
- Numéro de téléphone: 617-726-8228
- E-mail: dcoccaspofford@mgh.harvard.edu
-
Sous-enquêteur:
- Akshay Desai, MD, MPH
-
Sous-enquêteur:
- Michael Givertz, MD
-
Sous-enquêteur:
- Scott Solomon, MD
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Mayo Clinic
-
Chercheur principal:
- Barry Borlaug, MD
-
Sous-enquêteur:
- Margaret Redfield, MD
-
Contact:
- Matthew Adolphsen
- Numéro de téléphone: 507-422-5919
- E-mail: Adolphsen.Matthew@mayo.edu
-
-
North Carolina
-
Winston-Salem, North Carolina, États-Unis, 27157
- Pas encore de recrutement
- Wake Forest University
-
Contact:
- Ben Nelson
- Numéro de téléphone: 336-716-6789
-
Chercheur principal:
- Dalane Kitzman, MD
-
Sous-enquêteur:
- Alain Bertoni, MD, MPH
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- University of Pennsylvania
-
Contact:
- Tiffany Sharkoski
- Numéro de téléphone: 215-615-2354
-
Chercheur principal:
- Julio Chirinos, MD, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adults over 30 years of age.
La description
Inclusion Criteria:
HF Inclusion Criteria (HeartShare Registry)
- Age ≥30 years.
- Prior diagnosis of HF in the EHR (any left ventricular ejection fraction).
Non-HF Group Inclusion Criteria (HeartShare Registry)
- Age ≥30 years.
- No known prior diagnosis of HF or use of loop diuretics.
- No known prior history of BNP >100 pg/ml or NTproBNP >300 pg/ml, if prior laboratory tests are available in the EHR.
HFpEF Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
-
Age ≥30 years.
-
Left ventricular ejection fraction ≥50% measured by echocardiography.
-
Definition of HFpEF: signs and symptoms of HF, NYHA functional class II-IV, and at least one of the following:
- Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.
- Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography).
- Elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise).
- Elevated H2FPEF score26 (≥5) or HFA-PEFF27 score (≥5).
Non-HFpEF Group Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
- Age ≥30 years.
- Left ventricular ejection fraction ≥50% measured by echocardiography.
- No known prior diagnosis of HF or use of diuretics for fluid management.
- No known prior history of BNP ≥75 pg/ml or NTproBNP ≥225 pg/ml, if prior laboratory tests are available in the EHR.
- BNP <75 pg/ml or NTproBNP <225 pg/ml at the time of screening. Choice of BNP or NTproBNP is based on availability at each clinical center.
Exclusion Criteria:
Exclusion Criteria (HeartShare Registry) The following exclusion criteria apply to both HF and non-HF group participants, unless otherwise indicated.
- For non-HF group: any prior known left ventricular ejection fraction <50%.
- Prior history of solid organ transplantation.
- Prior history of mechanical circulatory support.
- Prior history of non-cardiac cirrhosis.
- Inability to provide written consent to the study.
Exclusion Criteria (HeartShare Deep Phenotyping Cohort) The following exclusion criteria apply to both HFpEF and non-HFpEF group participants, unless otherwise indicated.
-
Life expectancy estimated to be < 1 year.
-
Primary cardiomyopathy (including amyloid, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, or other infiltrative cardiomyopathies) or pulmonary arterial hypertension (WHO Group I, III, or IV pulmonary hypertension).
-
Any prior known left ventricular ejection fraction <40%, except if this occurred only in the setting of an acute tachycardia episode (e.g., acute atrial fibrillation).
-
Clinically significant valvular heart disease defined as:
- Moderate to greater aortic stenosis, pulmonic stenosis, or tricuspid stenosis.
- Any mitral stenosis.
- Moderate or greater aortic regurgitation.
- Greater than moderate mitral regurgitation.
-
Any planned cardiac surgery or cardiac intervention in the next 3 months.
-
Alternative primary reason for symptoms of shortness of breath and exercise intolerance in HFpEF participants in the opinion of the enrolling investigator.
-
Cardiac surgery, acute coronary syndrome, percutaneous coronary intervention, stroke, transient ischemic attack, or carotid intervention in the preceding 6 months prior to enrollment.
-
Known symptomatic epicardial coronary artery disease that is not revascularized.
-
Any non-elective hospitalization in the preceding 2 weeks.
-
Prior history of solid organ transplantation.
-
Prior history of chronic infection (HIV, hepatitis C, hepatitis B, tuberculosis) unless treated and not clinically active in the opinion of the enrolling investigator.
-
Prior history of mechanical circulatory support.
-
Prior history of non-cardiac cirrhosis.
-
Estimated GFR <20 ml/min/1.73m2 or currently on dialysis.
-
Any condition that may preclude participation or adherence to the study protocol, in the opinion of the enrolling investigator.
-
Inability to provide written consent to the study.
-
Current acute decompensated heart failure.
-
Currently pregnant.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
HFpEF
Participants with HFpEF |
|
Non-HFpEF
Participants without HFpEF |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Nombre de participants souffrant d'insuffisance cardiaque avec fraction d'éjection préservée (HFpEF)
Délai: Jusqu'à 5 ans
|
Jusqu'à 5 ans
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Sanjiv Shah, MD, Northwestern University
- Chaise d'étude: Svati Shah, MD, MHS, Duke University
- Chaise d'étude: Javed Butler, MPH, MBA, Baylor Scott and White Health
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STU00217900
- U54HL160273 (Subvention/contrat des NIH des États-Unis)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .